APOC3 and pancreatitis: Studies were included if they met the following criteria: adult participants (≥18 years) with FCS or fasting triglyceride levels ≥150 mg/dL; interventions involving olezarsen at any dose or schedule; study designs encompassing Phase 1-3 clinical trials, open-label extensions, or regulatory/industry reports containing human efficacy or safety data; outcomes measuring changes in triglycerides and/or ApoC-III, incidence of pancreatitis, or safety parameters; and publications available in English.